"A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia." by F. T. Awan

Selected Works of John M. Pagel, MD, PhD

Article

A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia.

Journal of Clinical Oncology (2011)

F. T. Awan, Georgia Regents University
J. M. Pagel, University of Washington
A. Goy, Hackensack University Medical Center
R. M. Rifkin, Baylor College of Medicine
B. J. Poiesz
A. R. Mato, Hackensack University Medical Center
S. C. Stromatt
J. C. Byrd, Ohio State University
U. Jaeger, Medical University of Vienna

Link

Disciplines

Publication Date

May 20, 2011

DOI

10.1200/jco.2011.29.15_suppl.e13053

Citation Information

F. T. Awan, J. M. Pagel, A. Goy, R. M. Rifkin, et al.. "A phase Ib/II open-label study to evaluate the safety and efficacy of TRU-016 in combination with bendamustine versus bendamustine alone in patients with relapsed chronic lymphocytic leukemia." Journal of Clinical Oncology Vol. 29 (2011)
Available at: http://works.bepress.com/john-pagel/176/